Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Akums Drugs will undertake this development and commercialization in India
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Subscribe To Our Newsletter & Stay Updated
